The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score prevents a full distress risk assessment. Despite a low Price/Sales ratio of 0.28 suggesting potential undervaluation, the company is unprofitable with negative earnings, a negative ROE of -47.48%, and deteriorating profitability metrics. While recent quarterly earnings have frequently beaten extremely low expectations—sometimes by over 1000%—this reflects poor baselines rather than sustainable progress, and long-term price performance remains deeply negative with a 5-year return of -93.9%. The stock trades significantly below analyst target prices, but fundamental weaknesses, lack of profitability, and inconsistent cash flow data undermine bullish sentiment.